Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 9, 2022Conference Call and Webcast to be Held at 4:30 p.m. EDT
-
Feb 24, 2022Interim analysis showed primary efficacy endpoint of cough reduction was highly statistically significant (p<0.0001) for Haduvio (nalbuphine ER)
-
Feb 1, 2022Top-Line Data Expected 2Q 2022
-
Jan 5, 2022Phase 2 CANAL (Chronic Cough in IPF) Planned Interim Statistical Update 1Q 2022, with Top-Line Data 1H 2022
-
Dec 16, 202111th Annual LifeSci Partners Corporate Access Event, January 5-7
-
Nov 10, 2021Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022
-
Nov 3, 2021Conference Call and Webcast to be Held at 4:30 p.m. ET
-
Sep 30, 2021Proceeds Will Fund the Development of Haduvio for Severe Chronic Pruritus in Prurigo Nodularis and Chronic Cough in Idiopathic Pulmonary Fibrosis
-
Aug 12, 2021Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022
-
Aug 9, 2021Key Management Appointments Support Company Growth as Lead Trials Move Towards Data
-
Aug 5, 2021Conference Call and Webcast to be Held at 4:30 p.m. ET
-
May 13, 2021Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Over 70% Enrolled
-
May 6, 2021Conference Call and Webcast to be Held at 4:30 p.m. ET
Media Contact
Katie McManus
(203) 903-9627
k.mcmanus@trevitherapeutics.com
Trevi Therapeutics
195 Church Street, 14th Floor
New Haven, CT 06510
map
Register to receive real time alerts